Wieslaw Szelejewski

This inventor holds 10 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Instytut Farmaceutyczny, Bs-154 S.p. Zo.o., Centrum Baden Molekularnych I Makromolekularnych -Pan. Active years: 1990-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wieslaw Szelejewski. Retrieved from https://idiyas.com/inventor/wieslaw-szelejewski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

% Patents Active = 10.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 7.6

ph-index = 2

Forward Citations = 16(Granted Patents)

Location History:

Warszawa, PL (2009 - 2011)
Warsaw, PL (1990 - 2015)

Company Filing History:

7 out of 10

Instytut Farmaceutyczny

Centrum Baden Molekularnych I Makromolekularnych -Pan

patent

4. 1 out of 1

Institut Farmaceutyczny

patent

5. 1 out of 7

Instytut Immunologii I Terapii Doswiadczalnej Pan

patents

6. 1 out of 2

Instytut Przemyslu Farmaceutycznego

patents

7. 1 out of 1

Zaklady Farmaceutyczne Polpharma

patent

where one patent can have more than one assignee

Years Active: 1990-2015

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9096536 - Asymmetrically substituted anthrapyridazone derivatives as cytostatics (2015-08-04),

2. 7928063 - Analogs of human growth hormone-releasing hormone, their preparation and use (2011-04-19),

3. 7915241 - Preparation of 24 alkyl analogs of cholecalciferol and non-racemic compounds (2011-03-29),

4. 7897793 - Process for preparation of 13,14-dihydro-PGF2 alpha derivatives (2011-03-01),

5. 7829746 - Process for the preparation of calcipotriol (2010-11-09),

6. 7732601 - Crystalline polymorphs of methanesulfonic acid addition salts of Imatinib (2010-06-08),

7. 7700580 - Process for preparation of pharmaceutically pure anhydrous calcipotriol (2010-04-20),

8. 7674901 - Process for preparation of imatinib base (2010-03-09),

9. 7538213 - Methods for preparation of olanzapine polymorphic form I (2009-05-26),

10. 4908464 - Process for the production of 1,3,2-oxazaphosphorinanes (1990-03-13),

Title: The Innovative Contributions of Wieslaw Szelejewski

Introduction

Wieslaw Szelejewski is a notable inventor based in Warsaw, Poland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cytostatics and growth hormone-releasing hormone analogs. With a total of 10 patents to his name, Szelejewski's work has had a profound impact on medical science.

Latest Patents

One of his latest patents is focused on asymmetrically substituted anthrapyridazone derivatives as cytostatics. This invention relates to new derivatives of 2,7-dihydro-3H-dibenzo[de,h]cinnoline-3,7-dione, which exhibit activity against tumor cells, especially those with multidrug resistance (MDR). The derivatives are represented by a specific general formula, showcasing their potential in cancer treatment.

Another significant patent involves analogs of human growth hormone-releasing hormone, which are designed to stimulate GH release effectively. These peptides are resistant to enzymatic degradation and are synthesized using solid-phase methods. The invention details the preparation of these peptides, highlighting their potential therapeutic applications.

Career Highlights

Wieslaw Szelejewski has worked with prominent companies in the pharmaceutical industry, including the Pharmaceutical Institute and Polpharma Pharmaceutical Works. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Throughout his career, Szelejewski has collaborated with notable colleagues such as Andrzej Kutner and Wojciech Szczepek. These partnerships have likely enhanced his research and development efforts, leading to successful innovations in the pharmaceutical field.

Conclusion

Wieslaw Szelejewski's contributions to the field of pharmaceuticals through his patents and collaborations demonstrate his commitment to advancing medical science. His innovative work continues to influence the development of effective treatments for various health conditions.

Profile summary based on public USPTO records.